Bladder Cancer - Pipeline Assessment and Market Forecasts to 2017


#41725

47pages

GlobalData

$ 2000

In Stock


GlobalData, the industry analysis specialist, has released its new report, “Bladder Cancer - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global bladder cancer therapeutics market. The report identifies the key trends shaping and driving the global bladder cancer therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. 

 

Most importantly, the report provides valuable insights on the pipeline products within the global bladder cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. The global bladder cancer therapeutics market was worth $577.5m in 2009. The market grew at a CAGR of 9.9% between 2001 and 2009. The bladder cancer therapeutics market was dominated by generics such as vinblastine, cisplatin and methotrexate, as well as Bacillus Calmette-Guérin (BCG) and mitomycin C. Gemzar is the only available branded drug that is approved for the treatment of bladder cancer. However, in 2009, the drug’s patent expired in Europe and subsequently, Gemzar faced competition from generic versions manufactured by companies such as Actavis. Between 2009 and 2017, the bladder cancer therapeutics market is expected to grow at a CAGR of 7.0%, due to the launch of three new promising therapies - EoQuin, Javlor (launched in the UK) and Urocidin. 

 

Scope

 

  • The report provides information on the key drivers and challenges of the bladder cancer therapeutics market. Its scope includes:
  • Annualized global bladder cancer therapeutics market revenues data from 2001 to 2009, forecast for eight years to 2017.
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as microtubule synthesis inhibitors, BCG refractory CIS Therapy, Growth factor inhibitors, Heat Shock Protein Blockers and gene therapies.
  • Analysis of the current and future competition in the global bladder cancer therapeutics market market. Key market players covered are Celldex Therapeutics, AstraZeneca, Bioniche and Sanofi-Aventis, Inc.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the bladder cancer therapeutics market.

Reasons to buy

 

  • The report will enhance your decision making capability. It will allow you to:
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global bladder cancer therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
  • What’s the next big thing in the global bladder cancer therapeutics market landscape? - Identify, understand and capitalize.


Table of Contents

1 Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Bladder Cancer: Introduction
2.1 Overview
2.2 Staging
2.3 Treatment
2.4 Epidemiology
2.5 Etiology
2.6 Clinical Features
2.7 Diagnosis
2.8 Prognosis
2.9 GlobalData Pipeline Report Guidance

3 Bladder Cancer Market: Market Characterization
3.1 Overview
3.2 Bladder Cancer Market Size
3.3 Bladder Cancer Market Forecast and CAGR
3.4 Drivers and Barriers for the Bladder Cancer Market
3.4.1 Drivers for the Bladder Cancer market
3.4.2 Barriers for the Bladder Cancer market
3.5 Opportunity and Unmet Need
3.5.1 Neoadjuvant Treatment
3.5.2 Metastatic Bladder Cancer Treatment
3.6 Key Takeaway

4 Bladder Cancer Market: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Bladder Cancer Market
4.3.1 TICE BCG
4.3.2 Valstar (Valrubicin)
4.3.3 PLATINOL-AQ (cisplatin Injection)
4.3.4 MVAC (Methotrexate, Vinblastine, Adriamycin and Cisplatin)
4.3.5 Gemcitabine + Cisplatin
4.4 Key Takeaway

5 Bladder Cancer Market: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.2.1 Technology Trends Analytic Framework
5.3 Bladder Cancer Therapeutics - Promising Drugs under Clinical Development
5.4 Molecule Profile for Promising Drugs under Clinical Development
5.4.1 Javlor (Bristol-Myers Squibb and Pierre Fabre Medicament S.A)
5.4.2 EoQuin (Spectrum Pharmaceuticals and Allergan Inc)
5.4.3 Urocidin (Bioniche Life Sciences and Endo Pharma)
5.4.4 Larotaxel (Sanofi Aventis)
5.4.5 OGX-427 (OncoGeneX Inc)
5.5 Bladder Cancer Therapeutics Market - Clinical Pipeline by Mechanism of Action
5.6 Bladder Cancer Pipeline - Pipeline by Clinical Phases of Development
5.6.1 Bladder Cancer Therapeutics - Phase III Clinical Pipeline
5.6.2 Bladder Cancer Therapeutics - Phase II Clinical Pipeline
5.6.3 Bladder Cancer Therapeutics - Phase I Clinical Pipeline
5.6.4 Bladder Cancer Therapeutics - Pre-clinical Pipeline
5.6.5 Discontinued / Suspended Drug for Bladder Cancer
5.7 Key Takeaway

6 Bladder Cancer Market: Implications for Future Market Competition

7 Bladder Cancer Market: Future Players in the Bladder Cancer Market

7.1 Introduction
7.2 AstraZeneca Plc.
7.2.1 Overview
7.2.2 Financial Performance
7.2.3 Bladder Cancer Portfolio
7.3 Sanofi-Aventis, France
7.3.1 Overview
7.3.2 Bladder Cancer Portfolio
7.4 Spectrum Pharmaceuticals
7.4.1 Overview
7.4.2 Oncology Portfolio
7.5 Bioniche Life Sciences
7.5.1 Overview
7.5.2 Oncology Portfolio
7.6 Celldex Therapeutics, Inc.
7.6.1 Overview
7.6.2 Financial Overview
7.6.3 Oncology Portfolio
7.7 Hoosier Oncology Group, Inc.
7.7.1 Overview
7.7.2 Oncology Portfolio

8 Bladder Cancer Market: Appendix
8.1 Definitions
8.2 Acronyms
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Primary Research
8.3.5 Expert Panel Validation
8.4 Contact Us
8.5 Disclaimer
8.6 Sources


Table 1: Bladder Cancer Therapeutics, Cancer Staging, 2010 6
Table 2: Bladder Cancer Therapeutics, Staging of Bladder Cancer, 2009 6
Table 3: Bladder Cancer Therapeutics, Treatment Options by Stage of the Disease, 2009 7
Table 4: Bladder Cancer Therapeutics, Prevalence by Country, 2009 7
Table 5: Bladder Cancer Therapeutics, Bladder Cancer Recurrence (%) by Stage, 2010 8
Table 6: Bladder Cancer Therapeutics, Global, Revenue ($bn), 2001-2009 11
Table 7: Global Bladder Cancer Market Revenue ($m), 2009-2017 12
Table 8: Major Marketed Products Comparison in the Bladder Cancer Market, 2010 23
Table 9: Bladder Cancer Therapeutics Most Promising Drugs Under Clinical Development, 2010 25
Table 10: Clinical Trial Results for Javlor, April 2009 27
Table 11: Bladder Cancer Therapeutics Phase III Clinical Pipeline 31
Table 12: Bladder Cancer Therapeutics Phase II Clinical Pipeline 32
Table 13: Bladder Cancer Therapeutics Phase I Clinical Pipeline 33
Table 14: Bladder Cancer Therapeutics Pre-clinical Pipeline 34
Table 15: TypeTableTitleHere 34
Table 16: AstraZeneca Oncology Pipeline Products, 2010 37
Table 17: Sanofi-Aventis Oncology Pipeline Products, 2010 38
Table 18: Spectrum Pharmaceuticals Oncology Pipeline Products, 2010 38
Table 19: Bioniche Life Sciences Oncology Pipeline Products, 2010 39
Table 20: Celldex Therapeutics Oncology Pipeline Products, 2010 39
Table 21: Hoosier Oncology Group, Inc. Oncology Pipeline Products, 2010 40


Figure 1: Bladder Cancer Therapeutics, Global, Revenue ($bn), 20012009 11
Figure 2: Bladder Cancer Therapeutics, Global, Market Forecast ($bn), 2009-2017 12
Figure 3: Opportunity and Unmet Need in the Superficial Bladder Cancer Market, 2010 14
Figure 4: Opportunity and Unmet Need in the Neo-adjuvant Treatment of Bladder Cancer, 2010 15
Figure 5: Opportunity and Unmet Need in the Metastatic Bladder Cancer Market, 2010 16
Figure 6: Strategic Competitor Assessment of the Major Marketed Products in Bladder Cancer, 2010 17
Figure 7: Technology Trends Analytic Framework of the Bladder Cancer Pipeline, 2010 24
Figure 8: Technology Trends Analytic Framework Description of the Bladder Cancer Pipeline, 2010 25
Figure 9: Bladder Cancer Therapeutics Market Clinical Pipeline by Mechanism of Action, 2010 30
Figure 10: Bladder Cancer Therapeutics Market Pipeline by Clinical Phase of Development 31
Figure 11: Implications for Future Market Competition in the Bladder Cancer Market, 2010 35
Figure 12: Bladder Cancer Market Clinical Pipeline by Company, 2010 36
Figure 13: GlobalData Market Forecasting Model 45